Insight, China's Pharmaceutical Industry

Novartis Acquires SNV4818 from Synnovation – USD 3 Billion Deal for Pan‑Mutant PI3Kα Inhibitor in Breast Cancer

Fineline Cube Mar 23, 2026

Novartis AG (NYSE: NVS) announced a definitive agreement to acquire SNV4818, a pan‑mutant‑selective PI3Kα inhibitor,...

Grand Pharma Wins NMPA Approval for GPN01768 – First Targeted Therapy for Demodex Blepharitis in China

Fineline Cube Mar 23, 2026

Grand Pharmaceutical Group (HKG: 0512) announced that its licensed‑in global innovative ophthalmic drug GPN01768 [TP‑03,...

Company Drug

GSK Wins FDA Approval for Lynavoy – First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close

Fineline Cube Mar 23, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has...

Company

Eli Lilly Submits Obesity Policy Recommendations at China Development Forum – Advocates for Weight Management in 15th Five‑Year Plan

Fineline Cube Mar 23, 2026

Eli Lilly and Company (NYSE: LLY) submitted a comprehensive policy recommendation paper at the China...

Company Drug

Xuanzhu Biopharma Completes Anaprazole Phase III Enrollment – 500‑Subject Reflux Esophagitis Trial Advances Novel PPI

Fineline Cube Mar 23, 2026

Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced completion of full enrollment for its Phase III...

Company Drug

Hengrui Pharma’s SHR-3836 Wins NMPA Approval for Multiple Myeloma – First-in-Class Anti-Tumor Agent Enters Clinical Development

Fineline Cube Mar 23, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its independently developed drug...

Company Drug

Hengrui Pharma’s HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer – Second Indication Expands Trastuzumab Rezetecan Franchise

Fineline Cube Mar 23, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its self-developed Category 1...

Company Drug

Innovent Biologics Doses First Patient in Phase 3 Tigulixostat Study – Next‑Gen Xanthine Oxidase Inhibitor Targets Gout Market

Fineline Cube Mar 23, 2026

Innovent Biologics, Inc. (HKG: 1801) announced that the first subject has been dosed in the...

Company Drug

Dizal Reports Positive WU‑KONG28 Results – ZEGFROVY First‑Line Win Positions as First Chemo‑Free EGFR exon20ins NSCLC Therapy

Fineline Cube Mar 23, 2026

Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that its multinational Phase 3 WU‑KONG28 study evaluating...

Company Drug

CSPC Pharma’s SYH2082 Wins NMPA Approval – Long‑Acting GLP‑1/GIP Dual‑Biased Agonist Enters Obesity Clinical Trials

Fineline Cube Mar 23, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self‑developed SYH2082, a long‑acting injectable GLP‑1/GIP...

Company Drug

Haihe Biopharma Wins Japan Approval for Risovalisib – First PI3Kα Inhibitor for Ovarian Clear Cell Carcinoma

Fineline Cube Mar 23, 2026

Haihe Biopharma Co., Ltd. announced that its independently developed selective PI3Kα inhibitor, Risovalisib Mesylate Tablets,...

Policy / Regulatory

China NHC Issues Medical Technology Evaluation Procedures – New Framework Triggers Restrictions or Bans on Controversial Clinical Practices

Fineline Cube Mar 23, 2026

China’s National Health Commission (NHC) issued the “Work Procedures for Evaluating the Clinical Application of...

Company Medical Device

Medtronic Completes First Penditure Implant in Greater Bay Area – Recapturable LAA Closure System Leverages HK‑Macao Access Policy

Fineline Cube Mar 20, 2026

Medtronic plc (NYSE: MDT) announced the first clinical implantation of its Penditure left atrial appendage...

Company Drug

3SBio Wins NMPA Approval for SSS06 – Extended‑Half‑Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia

Fineline Cube Mar 20, 2026

3SBio Inc. (HKG: 1530) announced that China’s National Medical Products Administration (NMPA) has approved SSS06,...

Company Drug

Alphamab Oncology Doses First Patient in JSKN016 Phase III – HER3/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer

Fineline Cube Mar 20, 2026

Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study for...

Company Drug

Belief BioMed Secures Macao Approval for BBM‑H901 – China’s First Hemophilia B Gene Therapy Expands to Greater China with Takeda

Fineline Cube Mar 20, 2026

Belief BioMed announced marketing approval from the Pharmaceutical Administration Bureau of Macao Special Administrative Region...

Company

Sanofi Opens Chengdu Innovation Hub – 600‑Headcount China Operations Center to Drive R&D and Commercial Excellence

Fineline Cube Mar 20, 2026

Sanofi S.A. (NASDAQ: SNY) has officially opened its China Innovation and Operations Hub in Chengdu,...

Company

AstraZeneca to Build Radioligand Therapy Manufacturing Hub in Guangzhou – Actinium‑225 Facility Targets Asia‑Pacific Cancer Market

Fineline Cube Mar 20, 2026

AstraZeneca PLC (NASDAQ: AZN) has signed a Memorandum of Understanding with the Guangzhou Economic and...

Company Drug

Novo Nordisk Wins FDA Approval for Wegovy HD 7.2 mg – Higher‑Dose Semaglutide Delivers 21% Weight Loss in STEP UP Trial

Fineline Cube Mar 20, 2026

Novo Nordisk A/S (NYSE: NVO) announced FDA approval of Wegovy HD (semaglutide) 7.2 mg injection,...

Company Drug

Eli Lilly’s Retatrutide Delivers 2.0% A1C Reduction and 36.6 Lbs Weight Loss in Phase 3 Diabetes Trial – Triple‑Agonist Shows Best‑in‑Class Efficacy

Fineline Cube Mar 20, 2026

Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 TRANSCEND‑T2D‑1...

Insight, China's Pharmaceutical Industry

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Novartis Acquires SNV4818 from Synnovation – USD 3 Billion Deal for Pan‑Mutant PI3Kα Inhibitor in Breast Cancer

Grand Pharma Wins NMPA Approval for GPN01768 – First Targeted Therapy for Demodex Blepharitis in China

GSK Wins FDA Approval for Lynavoy – First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close

Eli Lilly Submits Obesity Policy Recommendations at China Development Forum – Advocates for Weight Management in 15th Five‑Year Plan

Xuanzhu Biopharma Completes Anaprazole Phase III Enrollment – 500‑Subject Reflux Esophagitis Trial Advances Novel PPI

Hengrui Pharma’s SHR-3836 Wins NMPA Approval for Multiple Myeloma – First-in-Class Anti-Tumor Agent Enters Clinical Development

Hengrui Pharma’s HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer – Second Indication Expands Trastuzumab Rezetecan Franchise

Innovent Biologics Doses First Patient in Phase 3 Tigulixostat Study – Next‑Gen Xanthine Oxidase Inhibitor Targets Gout Market

Dizal Reports Positive WU‑KONG28 Results – ZEGFROVY First‑Line Win Positions as First Chemo‑Free EGFR exon20ins NSCLC Therapy

CSPC Pharma’s SYH2082 Wins NMPA Approval – Long‑Acting GLP‑1/GIP Dual‑Biased Agonist Enters Obesity Clinical Trials

Haihe Biopharma Wins Japan Approval for Risovalisib – First PI3Kα Inhibitor for Ovarian Clear Cell Carcinoma

China NHC Issues Medical Technology Evaluation Procedures – New Framework Triggers Restrictions or Bans on Controversial Clinical Practices

Medtronic Completes First Penditure Implant in Greater Bay Area – Recapturable LAA Closure System Leverages HK‑Macao Access Policy

3SBio Wins NMPA Approval for SSS06 – Extended‑Half‑Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia

Alphamab Oncology Doses First Patient in JSKN016 Phase III – HER3/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer

Belief BioMed Secures Macao Approval for BBM‑H901 – China’s First Hemophilia B Gene Therapy Expands to Greater China with Takeda

Sanofi Opens Chengdu Innovation Hub – 600‑Headcount China Operations Center to Drive R&D and Commercial Excellence

AstraZeneca to Build Radioligand Therapy Manufacturing Hub in Guangzhou – Actinium‑225 Facility Targets Asia‑Pacific Cancer Market

Novo Nordisk Wins FDA Approval for Wegovy HD 7.2 mg – Higher‑Dose Semaglutide Delivers 21% Weight Loss in STEP UP Trial

Eli Lilly’s Retatrutide Delivers 2.0% A1C Reduction and 36.6 Lbs Weight Loss in Phase 3 Diabetes Trial – Triple‑Agonist Shows Best‑in‑Class Efficacy

You Missed

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors